Achieve Life Sciences closed a private Placement of up to $354 million, receiving $180 million upfront, strengthening its Balance Sheet ahead of a planned FDA resubmission. The infusion improves liquidity, backs its Phase 3 trial and positions the stock for potential upside if cytisinicline gains approval.
Key Highlights
- EPS $‑0.19 versus consensus $‑0.31, narrowing the loss gap for the quarter ended March 31, 2026
- Cash, cash equivalents and marketable securities total $187.3 million following the funding round
- Achieve Life Sciences (NASDAQ: ACHV) raised $180 million upfront from a $354 million private placement, delivering a sizeable cash boost that underwrites its upcoming FDA resubmission.
Achieve Life Sciences (NASDAQ: ACHV) raised $180 million upfront from a $354 million private placement, delivering a sizeable cash boost that underwrites its upcoming FDA resubmission. The infusion arrives as the company reports an EPS of $‑0.19, outperforming the $‑0.31 consensus, and positions it for a key regulatory milestone.
Funding Round Details
The financing round provided $180 million in cash immediately, with the remaining $174 million tied to milestone‑based warrants exercisable within 20 trading days of FDA approval. The Capital will primarily fund the ORCA‑V2 Phase 3 trial and scale commercial infrastructure for cytisinicline. After the placement, cash, cash equivalents and marketable securities rose to $187.3 million, dwarfing prior balances.
Operating expenses for the six‑month period through June 30, 2026 amounted to $28.9 million, while net losses widened to $84.9 million, reflecting a $48.7 million non‑cash charge on Warrant fair‑value adjustments. The sizable cash cushion buffers the company against the high‑cost development cycle ahead.
Clinical and Regulatory Progress
The company received a Complete Response Letter on June 20, 2026, which raised no concerns about cytisinicline’s efficacy or safety, but highlighted cGMP observations at a former third‑party site. To address this, Achieve transitioned finished‑product Manufacturing to Adare Pharma Solutions in the United States, completing analytical method transfer and qualifying testing procedures. With the Facility ready, the firm plans to file a resubmission of its NDA naming Adare as the commercial manufacturer in Q4 2026, targeting potential approval in the first half of 2027.
Successful regulatory clearance would unlock a large U.S. market for nicotine dependence treatment.
Market Position and Performance
The stock’s 52‑week range of $2.45 to $7.11 reflects strong upside potential, especially given the recent Earnings beat where EPS improved relative to consensus. The reduced short‑interest coverage of 15.0 days suggests limited immediate pressure from short sellers. Combined with the fresh capital, the company is better equipped to sustain R&D spend and manage its expanding operational footprint.
Outlook and Upcoming Catalysts
Management signals that the next major event will be the NDA resubmission in the fourth quarter of 2026, a step that could trigger a substantial Revaluation if the FDA grants approval. The proceeds from the placement also enable the launch of the ORCA‑V2 trial, providing additional data to reinforce the product’s profile. Investors will watch for the filing date and any accompanying FDA commentary, which together will set the tone for the company’s valuation heading into 2027.
Peers Moving on This News
- Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) down 1.6%
- Shattuck Labs Inc (NASDAQ: STTK) down 2.5%






Please wait processing your request...